Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 51 articles:
HTML format



Single Articles


    October 2021
  1. TALLANTYRE EC, Vickaryous N, Anderson V, Asardag AN, et al
    COVID-19 vaccine response in people with multiple sclerosis.
    Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.
    PubMed     Abstract available


    September 2021
  2. KOCH MW, Kaur S, Sage K, Kim J, et al
    Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Sep 30. doi: 10.1002/ana.26239.
    PubMed     Abstract available


    August 2021
  3. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
    Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
    Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
    PubMed     Abstract available


  4. PAN S, Chan JR
    Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
    Ann Neurol. 2021 Aug 17. doi: 10.1002/ana.26196.
    PubMed     Abstract available


  5. KOLB H, Absinta M, Beck ES, Ha SK, et al
    7T MRI Differetiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.
    PubMed     Abstract available


    July 2021
  6. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
    MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
    PubMed     Abstract available


  7. GELIBTER S, Pisa M, Croese T, Finardi A, et al
    Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
    Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
    PubMed     Abstract available


  8. HAUSER SL
    Curing Multiple Sclerosis: How to Know When We're There?
    Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
    PubMed    


    May 2021
  9. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
    Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
    Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
    PubMed     Abstract available


  10. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    PubMed     Abstract available


    April 2021
  11. COX LM, Maghzi AH, Liu S, Tankou SK, et al
    The Gut Microbiome in Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
    PubMed     Abstract available


  12. PETZOLD A
    Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
    Ann Neurol. 2021;89:849-850.
    PubMed    


  13. WOSTYN P, Gibson CR, Mader TH
    Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
    Ann Neurol. 2021;89:849.
    PubMed    


  14. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    PubMed     Abstract available


    March 2021
  15. VANDEBERGH M, Andlauer TFM, Zhou Y, Mallants K, et al
    Genetic variation in WNT9B increases relapse hazard in multiple sclerosis.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26061.
    PubMed     Abstract available


  16. NOURBAKHSH B, Cordano C, Asteggiano C, Ruprecht K, et al
    Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062.
    PubMed     Abstract available


    February 2021
  17. DE MEO E, Bonacchi R, Moiola L, Colombo B, et al
    Early predictors of 9-year disability in pediatric multiple sclerosis.
    Ann Neurol. 2021 Feb 17. doi: 10.1002/ana.26052.
    PubMed     Abstract available


    January 2021
  18. SORMANI MP, De Rossi N, Schiavetti I, Carmisciano L, et al
    Disease modifying therapies and Covid-19 severity in Multiple Sclerosis.
    Ann Neurol. 2021 Jan 21. doi: 10.1002/ana.26028.
    PubMed     Abstract available


    November 2020
  19. THAM M, Frischer JM, Weigand SD, Fitz-Gibbon PD, et al
    Iron heterogeneity in early active multiple sclerosis lesions.
    Ann Neurol. 2020 Nov 27. doi: 10.1002/ana.25974.
    PubMed     Abstract available


  20. FADDA G, Banwell B, Waters P, Marrie RA, et al
    Silent new brain MRI lesions in children with MOG-antibody associated disease.
    Ann Neurol. 2020 Nov 19. doi: 10.1002/ana.25957.
    PubMed     Abstract available


    October 2020
  21. SOTIRCHOS ES, Calabresi PA, Saidha S
    Reply to "Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?"
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25936.
    PubMed    


  22. CORDANO C, Yiu HH, Oertel FC, Gelfand JM, et al
    Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25933.
    PubMed    


  23. COMI G, Bar-Or A, Lassmann H, Uccelli A, et al
    The role of B cells in Multiple Sclerosis and related disorders.
    Ann Neurol. 2020 Oct 9. doi: 10.1002/ana.25927.
    PubMed     Abstract available


    September 2020
  24. CIOTTI JR, Grebenciucova E, Moss BP, Newsome SD, et al
    Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25907.
    PubMed    


    August 2020
  25. MAGGI P, Sati P, Nair G, Cortese ICM, et al
    PARAMAGNETIC RIM LESIONS ARE SPECIFIC TO MULTIPLE SCLEROSIS: AN INTERNATIONAL MULTICENTER 3T MRI STUDY.
    Ann Neurol. 2020 Aug 15. doi: 10.1002/ana.25877.
    PubMed     Abstract available


  26. PETZOLD A, Coric D, Balk LJ, Hamann S, et al
    Longitudinal Development of Peripapillary Hyper-Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in Multiple Sclerosis.
    Ann Neurol. 2020;88:309-319.
    PubMed     Abstract available


    July 2020
  27. KHOURY SJ
    Progressive Multiple Sclerosis.
    Ann Neurol. 2020 Jul 6. doi: 10.1002/ana.25802.
    PubMed    


  28. KRYSKO KM, Graves JS, Rensel M, Weinstock-Guttman B, et al
    Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Ann Neurol. 2020;88:42-55.
    PubMed     Abstract available


    June 2020
  29. PETROVA N, Nutma E, Carassiti D, Newman J, et al
    Synaptic loss in the multiple sclerosis spinal cord.
    Ann Neurol. 2020 Jun 30. doi: 10.1002/ana.25835.
    PubMed     Abstract available


  30. FILIPPI M, Preziosa P, Langdon D, Lassmann H, et al
    Identifying Progression In Multiple Sclerosis: New Perspectives.
    Ann Neurol. 2020 Jun 7. doi: 10.1002/ana.25808.
    PubMed     Abstract available


  31. LEBRUN-FRENAY C, Kantarci O, Siva A, Sormani MP, et al
    Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.
    Ann Neurol. 2020 Jun 4. doi: 10.1002/ana.25799.
    PubMed     Abstract available


    May 2020
  32. MAGLIOZZI R, Scalfari A, Pisani AI, Ziccardi S, et al
    The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.
    Ann Neurol. 2020 May 17. doi: 10.1002/ana.25786.
    PubMed     Abstract available


  33. AMOR S, Baker D, Khoury SJ, Schmierer K, et al
    SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
    Ann Neurol. 2020 May 8. doi: 10.1002/ana.25770.
    PubMed     Abstract available


  34. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    PubMed    


    April 2020
  35. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    PubMed    


  36. DESAI RA, Davies AL, Del Rossi N, Tachrount M, et al
    Nimodipine reduces dysfunction and demyelination in models of multiple sclerosis.
    Ann Neurol. 2020 Apr 15. doi: 10.1002/ana.25749.
    PubMed     Abstract available


  37. MAHAJAN KR, Nakamura K, Cohen JA, Trapp BD, et al
    Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25743.
    PubMed     Abstract available


  38. COLE JH, Raffel J, Friede T, Eshaghi A, et al
    Longitudinal assessment of multiple sclerosis with the brain-age paradigm.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25746.
    PubMed     Abstract available


  39. SOTIRCHOS ES, Caldito NG, Filippatou A, Fitzgerald KC, et al
    Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy.
    Ann Neurol. 2020 Apr 13. doi: 10.1002/ana.25738.
    PubMed     Abstract available


    March 2020
  40. DE MOL CL, Jansen PR, Muetzel RL, Knol MJ, et al
    Polygenic multiple sclerosis risk and population-based childhood brain imaging.
    Ann Neurol. 2020 Mar 12. doi: 10.1002/ana.25717.
    PubMed     Abstract available


    February 2020
  41. OUELLETTE R, Mangeat G, Polyak I, Warntjes M, et al
    Validation of rapid magnetic resonance myelin imaging in multiple sclerosis.
    Ann Neurol. 2020 Feb 14. doi: 10.1002/ana.25705.
    PubMed     Abstract available


  42. ALPING P, Askling J, Burman J, Fink K, et al
    Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients.
    Ann Neurol. 2020 Feb 13. doi: 10.1002/ana.25701.
    PubMed     Abstract available


    January 2020
  43. OLDONI E, Smets I, Mallants K, Vandebergh M, et al
    CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity.
    Ann Neurol. 2020 Jan 29. doi: 10.1002/ana.25691.
    PubMed     Abstract available


  44. DOBSON R, Jitlal M, Marshall CR, Noyce AJ, et al
    Ethnic and socioeconomic associations with multiple sclerosis risk.
    Ann Neurol. 2020 Jan 23. doi: 10.1002/ana.25688.
    PubMed     Abstract available


  45. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    PubMed     Abstract available


    November 2019
  46. CHUNG KK, Altmann D, Barkhof F, Miszkiel K, et al
    A thirty year clinical and MRI observational study of multiple sclerosis and clinically isolated syndromes.
    Ann Neurol. 2019 Nov 6. doi: 10.1002/ana.25637.
    PubMed     Abstract available


    August 2019
  47. LOONSTRA FC, Verberk IMW, Wijburg MT, Wattjes MP, et al
    Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Ann Neurol. 2019;86:322-324.
    PubMed    


  48. DALLA COSTA G, Martinelli V, Furlan R, Comi G, et al
    Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Ann Neurol. 2019;86:324.
    PubMed    


    May 2019
  49. NOLAN-KENNEY RC, Liu M, Akhand O, Calabresi PA, et al
    Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.
    Ann Neurol. 2019;85:618-629.
    PubMed     Abstract available


    February 2019
  50. DALLA COSTA G, Martinelli V, Moiola L, Sangalli F, et al
    Serum neurofilaments increase at PML onset in natalizumab-treated MS patients.
    Ann Neurol. 2019 Feb 13. doi: 10.1002/ana.25437.
    PubMed     Abstract available


    January 2019
  51. CACCIAGUERRA L, Meani A, Mesaros S, Radaelli M, et al
    Brain and cord imaging features in neuromyelitis optica spectrum disorders.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25411.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: